Company page

Passage Bio, Inc.

Passage Bio, Inc. is a public company traded under the ticker PASG in the American market. The company has a market capitalization of approximately $15.5 million. Passage Bio focuses on developing gene therapies for neurological diseases, aiming to address significant unmet medical needs in this area.